In a 2020 study published in JAMA Psychiatry, researchers gave experienced cannabis users products ranging from 16% to 24% THC flower. The users couldn’t reliably tell which was which. Potency labels predicted almost nothing about subjective experience or psychomotor impairment. The cannabis industry has spent a decade running a THC arms race. The research keeps suggesting it’s largely a marketing phenomenon. What actually determines how a cannabis product feels is more interesting than a percentage on a label, and considerably more useful to understand.
🧪 Lab Tested | 👩💼 Woman-Owned | 🏆 Est. 2017
The THC Arms Race and How It Started
Cannabis THC percentages have climbed steadily for decades. In the 1990s, average THC content in seized cannabis samples was around 4%. By 2022, the average in legal market flower was above 20%, with some products claiming 30% or higher. The forces behind this are entirely market-driven: dispensaries found that customers reliably chose higher-percentage products when given a number to compare. Breeders responded by selecting for THC expression. Labs responded with testing methodologies that tended toward higher readings. The percentage became the proxy for quality, and quality became synonymous with strength.
The problem is that THC percentage was never a particularly good proxy for quality, and the research has been trying to say so for years. The 2020 JAMA Psychiatry study is one of several that found weak or absent correlations between THC content and subjective experience in controlled settings. A 2021 study in Psychopharmacology found that CBD-to-THC ratio predicted anxiety response better than THC concentration alone. Earlier work from Ethan Russo’s group established that terpene profiles modulate the subjective character of THC’s effects through what’s now broadly called the entourage effect.
None of this means THC is irrelevant. It means the percentage on a label is capturing one variable in a multi-variable equation and presenting it as if it’s the whole story.
Tolerance and the CB1 Ceiling Effect
CB1 receptors, the primary targets of THC in the brain, downregulate with consistent exposure. The body literally reduces receptor availability in response to repeated activation. This means two things that work against the high-THC logic.
First, habitual users need progressively higher doses to achieve the same receptor occupancy. But the ceiling isn’t linear. At high tolerance, the relationship between dose and effect flattens significantly. Going from 20% THC flower to 30% THC flower at high tolerance produces a much smaller experiential difference than going from 3% to 10% would produce in a naive user. The marginal return on additional THC decreases as tolerance increases.
Second, CB1 downregulation specifically impairs the THC-driven effects while leaving terpene-mediated effects more intact. Terpenes interact with serotonin, GABA, and dopamine receptors that don’t downregulate in the same way as CB1. A high-tolerance user who switches to a lower-THC product with a richer terpene profile sometimes reports a more satisfying experience than they were getting from progressively higher-THC options, precisely because the terpene contributions hadn’t been tolerance-blunted.
For new and low-tolerance users, THC percentage matters significantly. The dose-response curve is steep and the margin between “comfortable” and “too much” is narrow. Starting low regardless of percentage is the correct protocol. But for experienced users making quality comparisons at the top end of the market, chasing the highest THC number is chasing diminishing returns.
Why Terpenes Predict Experience Better Than THC
The entourage effect describes the interaction between cannabinoids and terpenes that shapes the subjective character of cannabis use. It’s not a fringe theory. The underlying pharmacology is documented across peer-reviewed literature, with Russo’s 2011 paper in the British Journal of Pharmacology still the most cited foundation for how terpene-cannabinoid interaction shapes clinical effects.
Two products with identical THC percentages but different terpene profiles will feel meaningfully different. This is why experienced consumers with access to lab data often describe choosing products based on terpene profile rather than potency.
Myrcene + High THC
Myrcene is a CNS depressant and potentiates cannabinoid absorption by increasing blood-brain barrier permeability. High-myrcene products feel stronger than their THC percentage suggests because more THC reaches its targets per milligram. A 20% THC product with 1.5% myrcene may feel more potent than a 28% product with 0.2% myrcene.
Limonene + THC
Limonene activates 5-HT1A serotonin and D2 dopamine receptors with an anxiolytic and mood-brightening effect. It buffers the anxiety that can accompany high CB1 occupancy. High-limonene products at the same THC content feel more manageable and less anxiety-prone than low-limonene products.
Beta-caryophyllene + THC
Beta-caryophyllene binds CB2 receptors directly, adding an anti-inflammatory physical comfort layer that doesn’t come from THC alone. Products with meaningful caryophyllene (0.3% and above) feel physically smoother. The body effect is broader and easier without additional THC.
Terpinolene + THC
Terpinolene produces cerebral alertness at typical concentrations. A high-terpinolene product at 18% THC will feel more cognitively stimulating than a low-terpinolene product at 25% THC. Strain character (cerebral vs. sedating) is predicted more reliably by dominant terpene than by THC concentration.
A well-grown, full-terpene product at 18% THC consistently outperforms a terpene-degraded product at 28% for the users who can tell the difference.
What Minor Cannabinoids Add
THC occupies most of the label, but the minor cannabinoids shape the texture of the experience in ways that raw THC percentage doesn’t capture.
CBD alongside THC
CBD is a negative allosteric modulator at CB1 receptors, which means it reduces the strength of THC’s binding without blocking it. High CBD:THC ratios produce a less intense, more functional psychoactive effect. CBD also acts on 5-HT1A receptors with anxiolytic activity that directly buffers THC-induced anxiety. A product with 15% THC and meaningful CBD will often feel more manageable than a 30% THC isolate product for anxiety-prone users.
CBG alongside THC
CBG acts on alpha-2 adrenoceptors, CB1 receptors (as a partial agonist), and 5-HT1A receptors. In combination with THC, CBG adds a physically comfortable, anxiety-reducing quality that users sometimes describe as a cleaner or clearer version of the THC effect. It’s one reason why some full-spectrum products feel distinctly different from distillate-based products even at the same THC concentration.
CBN alongside THC
CBN appears in aging cannabis as THC oxidizes. It’s associated with sedating, sleep-adjacent effects in combination with THC. A product high in CBN relative to other minor cannabinoids tends to produce heavier body effects. CBN isn’t about potency; it’s about the direction the effect takes.
THC in isolation
Distillate-based products (vape carts, edibles) often strip away terpenes and minor cannabinoids during processing, leaving THC at high concentrations with minimal supporting compounds. Many experienced users report that high-THC distillate products feel “flat” or “one-dimensional” compared to full-spectrum options at lower THC concentrations.
When THC Content Actually Does Matter
- New and low-tolerance users. For someone with no established CB1 tolerance, the dose-response curve is steep and the threshold for uncomfortable effects is low. THC percentage matters a lot here because small differences in milligrams produce large differences in experience. The correct protocol is to start with the lowest THC concentration available, regardless of terpene profile.
- Edibles with precise dosing needs. When the delivery format is an edible and you need predictable dosing, THC milligrams per serving is the number that matters. Edible onset is slow, the dose commits at ingestion, and small milligram differences compound over time. The COA milligram-per-serving figure is the critical data point for edible safety and predictability.
- Therapeutic use at meaningful doses. Some users incorporate cannabis products into pain, sleep, or symptom management routines where a certain threshold of CB1 activation is required. For these users, the minimum effective THC dose matters and choosing a product below it won’t achieve the intended effect. This is a case where THC concentration is a real clinical variable.
- Comparing products within the same format and terpene class. If two products have identical terpene profiles and you’re choosing between 18% and 22% THC, the higher percentage will likely produce a stronger effect. THC percentage is a useful differentiator when all other variables are held constant. The problem is that they rarely are in real-world purchasing decisions.
What to Look at on a COA Instead
Dominant terpene: The single most predictive COA variable for effect character. Myrcene-dominant = body relaxation, sedation-leaning. Limonene-dominant = mood uplift, sativa-leaning. Terpinolene-dominant = cerebral, heady. Beta-caryophyllene prominent = physical comfort, anti-anxiety. If the COA doesn’t include terpene data, you’re missing the most useful section.
Total terpene percentage. Beyond the dominant terpene, total terpene content is a proxy for how much of the entourage effect is available in the product. Products with total terpenes above 2% carry significantly more terpene-mediated effect than those at 0.5%. Live resin products preserve terpenes better than distillate-based products, and experienced users who can tell the difference usually attribute it to this.
Cannabinoid ratio (not just THC percentage). How much CBD, CBG, or CBN is present alongside the THC tells you about the character of the CB1 activation, not just the intensity. A 1:1 CBD:THC ratio product produces a fundamentally different experience from a pure THC product at the same concentration. These ratios appear in the cannabinoid panel and are often more meaningful than the THC number alone.
Format and extraction method. Live resin preserves terpenes through rapid low-temperature processing immediately after harvest. Distillate strips them for purity and long shelf life. For vape products, the label “live resin” or “live rosin” is a meaningful quality signal that often correlates with better terpene retention. It’s a production method claim, and the COA terpene panel is how you verify it.
TribeTokes posts COAs for all products at tribetokes.com/certificates-of-analysis. For a full guide on reading what each section of a COA means, see How to Read Cannabis Lab Results (COA).
Frequently Asked Questions
Not reliably. A 2020 study in JAMA Psychiatry found that experienced cannabis users couldn’t reliably distinguish high-THC from lower-THC products in blind tests. Potency labels were weak predictors of subjective experience. Terpene profile, minor cannabinoid content, tolerance level, and consumption format all affect the experience more consistently than THC percentage alone at the upper end of the potency range.
For new and low-tolerance users, yes. The difference matters because the dose-response curve is steep early. For experienced users with established tolerance, the difference is often negligible. CB1 receptor downregulation flattens the relationship between THC concentration and effect intensity at high tolerance. The marginal experiential difference between 20% and 30% THC at high tolerance is much smaller than the difference between 5% and 15% at low tolerance.
The entourage effect describes the synergistic interaction between cannabinoids and terpenes that shapes the character of the cannabis experience. Terpenes are not passive flavor compounds. They interact with serotonin, dopamine, GABA, and CB2 receptors in ways that modify how THC feels. Myrcene potentiates cannabinoid absorption and adds sedation. Limonene buffers anxiety. Beta-caryophyllene adds physical comfort through CB2 binding. The combined profile produces an experience the individual compounds couldn’t produce alone.
Terpene profile is the most common explanation. Myrcene increases blood-brain barrier permeability, which means more THC reaches its targets per milligram consumed. A product with 20% THC and 1.5% myrcene may deliver more THC to the brain than a 28% product with 0.2% myrcene. Extraction method also matters: live resin products preserve terpenes that distillate products lose, often producing a fuller effect at equivalent THC concentrations.
The dominant terpene is the single most predictive data point for effect character. Total terpene percentage indicates how much entourage effect is available. The cannabinoid ratio (how much CBD, CBG, or CBN is present alongside THC) shapes the character of CB1 activation. For inhaled products, live resin designation with a full terpene panel is a better quality signal than a high THC percentage with minimal terpenes.
CBD acts as a negative allosteric modulator at CB1 receptors, which reduces the maximum binding strength of THC without blocking it. The practical effect at typical 1:1 or 2:1 CBD:THC ratios is a less intense but often more functional and less anxiety-prone experience. CBD also has its own 5-HT1A anxiolytic activity that directly counteracts one of the most common adverse effects of THC. For anxiety-prone users, meaningful CBD alongside THC often produces a more manageable experience than equivalent THC alone.
Live resin preserves the terpene profile of the fresh plant through rapid low-temperature processing. Distillate removes terpenes to produce a purer, more shelf-stable concentrate. For users who experience the entourage effect, live resin products often feel more satisfying at equivalent THC concentrations because the terpenes are intact. Distillate products are more consistent batch-to-batch and carry higher THC concentrations, which may matter for precise edible dosing. Neither is categorically better. The right choice depends on what the user values.
Because consumers buy it. Multiple studies have found that THC percentage is the primary purchasing criterion for legal market cannabis consumers, even among experienced users. Dispensaries stock what sells. Breeders develop what dispensaries order. The percentage climbed not because it consistently improves the experience but because it consistently improves the sale. The research is catching up to what some experienced users and growers have known for a while: terpene quality and cannabinoid ratio tell a more complete story than a single number.
The Terpene Panel Tells You More. We Post Ours for Every Batch.
Third-party tested. ISO-accredited lab. Full terpene COA on every product.
